Investors will closely watch Indias Manufacturing PMI data today and the US JOLTS job openings report tomorrow. Key earnings scheduled for release include State
Author: techrossm
Apple Stock Is Trending Down: What’s Going On?
Apple Inc (NASDAQ:AAPL) shares are sliding on Monday after climbing to new highs last week. Here’s a look at what’s going on.
Why Kimberly-Clark Stock Just Dropped
Kimberly-Clark is promising to pay Kenvue shareholders $3.50 in cash, plus 0.14625 Kimberly-Clark shares, for each Kenvue share they own. K-C puts the total
Here’s How Much Traders Expect Palantir Stock To Move After Monday’s Earnings
Palantir is set to report its latest quarterly results after the closing bell Monday, with traders expecting a big move from the AI software
Stock market is in ‘classic price bubble,’ says Rosenberg Research founder David Rosenberg
David Rosenberg, founder and president of Rosenberg Research, joins CNBC’s ‘Money Movers’ to discuss macro outlooks.
Kimberly-Clark Stock Heads for Biggest One-Day Drop Since Black Monday
Kimberly-Clark shares were on track for their biggest one-day drop since the 1980s after the Huggies diapers maker agreed to buy Kenvue. Shares in
Inside AI’s rapid expansion: What investors need to know
How is AI changing markets and investment strategy? We analyze how AI adoption across hardware, software, and enterprise services is reshaping markets and redefining
Big Tech Extends Its Stock Market Dominance, Reviving Echoes to Dot-com Bubble
Tech’s market dominance is raising concerns that megacap tech giants are exhibiting echoes to the dot-com era peak of the early 2000s.
Stock indexes mostly gain after Amazon-OpenAI deal; dollar up slightly
Most major stock indexes were higher on Monday following news Amazon.com will supply cloud-computing services to OpenAI, and the dollar hovered near a three-month
UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enough – here’s what investors need to know
UniQure NV’s stock plummeted over 54% after the FDA deemed the clinical data for its Huntington’s disease gene therapy AMT-130 inadequate. Investors are left